J&J (JNJ) Close to Mult-Billion Dollar Settlement Over Illegal Anitpsychotic Drug Marketing
Tweet Send to a FriendGet Alerts JNJ Hot Sheet
Price: $88.01 -0.09%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 3%
EPS Growth %: +5.1%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 3%
EPS Growth %: +5.1%
Trade JNJ Now!
Johnson & Johnson (NYSE: JNJ) might soon settle litigation related to the marketing of one of its most popular drugs, Risperdal, for the treatment of schizophrenia. The Justice Department's claims suggest J&J may have illegally went beyond FDA regulation in an attempt to promote the product for unintended uses.
The latest rumor is for a settlement in the $1.5 billion to $2.0 billion range, according to several sources. In addition, J&J might be subject to paying penalties in each state the drug was sold, which could add a substantial amount to the total.
Reuters pointed out doctors are free to prescribe whatever medication they see fit for a treatment, but drug companies are limited on the scope of promotion they can pursue.
As the company announced last month it would take a $600 million one-time charge for any pending settlements (in addition to a $1.1 billion charge taken in the fourth quarter of last year), shares of J&J are largely unchanged in early trading Thursday.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The latest rumor is for a settlement in the $1.5 billion to $2.0 billion range, according to several sources. In addition, J&J might be subject to paying penalties in each state the drug was sold, which could add a substantial amount to the total.
Reuters pointed out doctors are free to prescribe whatever medication they see fit for a treatment, but drug companies are limited on the scope of promotion they can pursue.
As the company announced last month it would take a $600 million one-time charge for any pending settlements (in addition to a $1.1 billion charge taken in the fourth quarter of last year), shares of J&J are largely unchanged in early trading Thursday.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Senate Takes Aim at Apple (AAPL); Says Irish Unit Earned $22B, Paid $10M in Taxes
- Dean Foods (DF) Determines Ratio for Spin-Off of WhiteWave Foods (WWAV) Holding
- Royalty Pharma Raises Elan (ELN) Bid to $12.50/share
Create E-mail Alert Related Categories
Corporate News, Litigation, RumorsComments
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
Risperdal reproached
Daniel Haszard on Jun 21, 2012 08:54 AMMark as Spam | Reply to this comment
Reg; J& J Risperdal scandal fine
Thank you for reporting this breaking news,the atypical antipsychotic drug promoters are ‘reaping the whirlwind’.My case was with Eli Lilly Zyprexa same saga.
Four years of off-label Zyprexa use gave me life-long diabetes.-Daniel Haszard
FMI http://www.zyprexa-victims.com
(Risperdal is cousin of Zyprexa except that J&J is not getting any mercy because of association with family care products.)